Investigating the Safety and Efficacy of SHR6508 Injection in the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients : A Multicenter, Long-term Clinical Trial
This is a multicenter, single-arm, long-term safety and tolerability trial. A total of 300 subjects with chronic kidney disease on hemodialysis are planned to be enrolled.
Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis
DRUG: SHR6508
Incidence and severity of any adverse events that occurred during the clinical study, through study completion, an average of 1 year
Percent change from baseline in predialysis iPTH during the EAP, through study completion, an average of 1 year|Percent change from baseline in predialysis serum cCa during the EAP, through study completion, an average of 1 year|Percent change from baseline in predialysis serum phosphorus during the EAP, through study completion, an average of 1 year|Percent change from baseline in predialysis calcium-phosphorus product during the EAP, through study completion, an average of 1 year
This is a multicenter, single-arm, long-term safety and tolerability trial. A total of 300 subjects with chronic kidney disease on hemodialysis are planned to be enrolled.